Cytokinetics Inc (NASDAQ: CYTK) is -13.86% lower on its value in year-to-date trading and has touched a low of $37.46 and a high of $75.71 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The CYTK stock was last observed hovering at around $40.25 in the last trading session, with the day’s gains setting it 0.27%.
Currently trading at $40.52, the stock is -6.14% and -10.41% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 2.74 million and changing 0.67% at the moment leaves the stock -20.88% off its SMA200. CYTK registered -42.91% loss for a year compared to 6-month loss of -22.97%. The firm has a 50-day simple moving average (SMA 50) of $45.2304 and a 200-day simple moving average (SMA200) of $51.2162.
The stock witnessed a -7.66% gain in the last 1 month and extending the period to 3 months gives it a -13.86%, and is -5.75% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.51% over the week and 5.48% over the month.
Cytokinetics Inc (CYTK) has around 498 employees, a market worth around $4.80B and $18.47M in sales. Profit margin for the company is -3191.11%. Distance from 52-week low is 8.17% and -46.48% from its 52-week high. The company has generated returns on investments over the last 12 months (-94.66%).
The EPS is expected to shrink by -8.38% this year
475.0 institutions hold shares in Cytokinetics Inc (CYTK), with institutional investors hold 115.34% of the company’s shares. The shares outstanding are 118.21M, and float is at 115.43M with Short Float at 12.32%. Institutions hold 114.67% of the Float.
The top institutional shareholder in the company is BLACKROCK INC. with over 14.67 million shares valued at $794.97 million. The investor’s holdings represent 13.4317 of the CYTK Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 11.44 million shares valued at $619.69 million to account for 11.2218 of the shares outstanding. The other top investors are FMR LLC which holds 11.52 million shares representing 10.5485 and valued at over $624.32 million, while T. ROWE PRICE INVESTMENT MANAGEMENT, INC. holds 7.4503 of the shares totaling 8.14 million with a market value of $440.95 million.
Cytokinetics Inc (CYTK) Insider Activity
The most recent transaction is an insider sale by Blum Robert I, the company’s President & CEO. SEC filings show that Blum Robert I sold 15,000 shares of the company’s common stock on Mar 31 ’25 at a price of $40.75 per share for a total of $0.61 million. Following the sale, the insider now owns 0.43 million shares.
Cytokinetics Inc disclosed in a document filed with the SEC on Mar 18 ’25 that Malik Fady Ibraham (EVP Research & Development) sold a total of 2,000 shares of the company’s common stock. The trade occurred on Mar 18 ’25 and was made at $43.58 per share for $87160.0. Following the transaction, the insider now directly holds 0.14 million shares of the CYTK stock.
Still, SEC filings show that on Mar 17 ’25, Callos Andrew (EVP, Chief Commercial Officer) disposed off 2,775 shares at an average price of $44.38 for $0.12 million. The insider now directly holds 34,888 shares of Cytokinetics Inc (CYTK).
